While the latter exception authorizes a generic producer to use a patented substance for purposes reasonably related to the granting of marketing approval through a DRA, some countries’ laws on clinical test data prevent the DR A from relying, for a certain period of time, on the originator’s previously submitted clinical data for the purpose of approving a bioequivalent generic product. This wait will cause a considerable delay in the granting of regulatory approval for the generic drugs, which is contrary to the purpose of the regulatory review exception. Rather than leaving the task of patent enforcement up to the patentee, these laws turn the DRA into a patent enforcement authority, despite the fact that many of these authorities, especially in developing countries, do not have the expertise to verify the patent status of a drug. These will be discussed in the context of clinical test data protection (see Section 3.5).